Adaptimmune company

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom. Stock Symbol: NASDAQ:ADA
Technology: P4 Medicine
Industry: Preventive Medicine
Headquarters: Oxton, York, United Kingdom
Founded Date: 2008
Employees Number: 51-100
Funding Status: IPO
Investors Number: 14
Total Funding: $249.5M
Estimated Revenue: Less than $1M
Last Funding Type: Post-IPO Equity

Visit Website
info@adaptimmune.com
@Adaptimmune
Register and Claim Ownership